Secondary Logo

Journal Logo

The Role of Biomechanics and Inflammation in Cartilage Injury and Repair

Guilak, Farshid*†; Fermor, Beverley*; Keefe, Francis, J; Kraus, Virginia, B; Olson, Steven, A*; Pisetsky, David, S§∥; Setton, Lori, A*†; Weinberg, J, Brice§∥

Section Editor(s): Olson, Steven A MD, Guest Editor; Marsh, J Lawrence MD, Guest Editor

Clinical Orthopaedics and Related Research: June 2004 - Volume 423 - Issue - p 17-26
doi: 10.1097/01.blo.0000131233.83640.91
SECTION I: SYMPOSIUM: Articular Fractures
Free
SDC

Osteoarthritis is a painful and debilitating disease characterized by progressive degenerative changes in the articular cartilage and other joint tissues. Biomechanical factors play a critical role in the initiation and progression of this disease, as evidenced by clinical and animal studies of alterations in the mechanical environment of the joint caused by trauma, joint instability, disuse, or obesity. The onset of these changes after joint injury generally has been termed posttraumatic arthritis and can be accelerated by factors such as a displaced articular fracture. Within this context, there is considerable evidence that interactions between biomechanical factors and proinflammatory mediators are involved in the progression of cartilage degeneration in posttraumatic arthritis. In vivo studies have shown increased concentrations of inflammatory cytokines and mediators in the joint in mechanically induced models of osteoarthritis. In vitro explant studies confirm that mechanical load is a potent regulator of matrix metabolism, cell viability, and the production of proinflammatory mediators such as nitric oxide and prostaglandin E2. Knowledge of the interaction of inflammatory and biomechanical factors in regulating cartilage metabolism would be beneficial to an understanding of the etiopathogenesis of posttraumatic osteoarthritis and in the improvement of therapies for joint injury.

From the *Department of Surgery, Duke University Medical Center, Durham, NC; †Department of Biomedical Engineering, Duke University, Durham, NC; ‡Department of Psychiatry, Duke University Medical Center, Durham, NC, §Department of Medicine, Duke University Medical Center, Durham, NC; and the Department of Medicine, VA Medical Center, Durham, NC.

The institutions of the authors have received funding from the National Institutes of Health Grants AR50245, AG15768, AR47920, AR48182, and the VA Rehabilitation Research Service.

Correspondence to: Farshid Guilak, PhD, Orthopaedic Research Laboratories, Box 3093, 375 MSRB, Duke University Medical Center, Durham, NC 27710. Phone: 919-684-2521; Fax: 919-681-8490; E-mail: guilak@duke.edu.

Articular cartilage is the connective tissue that lines the ends of bones in all diarthrodial joints. This tissue serves important biomechanical functions in supporting and distributing forces generated during joint loading and provides a low-friction lubricating surface to prevent wear or degradation of the joint.102 Isolated cartilage lesions or intraarticular fractures may lead to progressive damage and degenerative joint conditions such as osteoarthritis (OA). Osteoarthritis manifests as a slowly progressing debilitating disease that affects one or more joints of the body. Clinical symptoms include pain, swelling, enlargement of the joints, and a decreased range of joint motion. Radiographic changes often are apparent and include joint space narrowing, osteophytes, cysts, and subchondral sclerosis. The primary pathologic changes of OA are fibrillation and loss of the articular cartilage, accompanied by thickening and remodeling of the subchondral bone. Osteoarthritis seems to be the common end point of numerous potentially independent pathologic processes that culminate in a loss of joint function.15,68,78,79,126

The development of these changes after joint injury generally has been termed posttraumatic arthritis and can be accelerated by factors such as a displaced intraarticular fracture. However, joint injury may involve additional factors that can contribute to the progression of OA, such as the initial impact(s) of the cartilage,105 soft tissue injuries and resulting joint instability,59,133 the quality of the reduction,83 or the introduction of blood in the joint.67 Furthermore, the incidence of OA after joint injury can depend considerably on which joint is affected.93 Considering the impact and consequences of posttraumatic arthritis, its etiology is not fully understood. It is now apparent that cartilage loss and joint destruction in OA can be influenced by a combination of genetic, age-related, and environmental factors such as soluble mediators (growth factors and cytokines) and biomechanical stress. Increasing evidence suggests that increased concentrations of inflammatory mediators, coupled with alterations in the mechanical environment of the cartilage, may influence the fate of the joint after injury. We review the potential roles of some of these modulators of cartilage physiology and their interactions in the health, injury, and repair of articular cartilage within the context of articular fractures and posttraumatic arthritis.

Back to Top | Article Outline

Mechanical Stress: A Regulator of Cartilage Health and Metabolism

Biomechanical factors play important roles in the health and function of the diarthrodial joint.64 For example, clinical data indicate that various exercises are safe and are not associated with an increased risk for joint disease.80 In fact, exercise has been shown to be an effective therapy for individuals with OA157 and has been strongly recommended in OA treatment guidelines by the American College of Rheumatology.7 Furthermore, obesity is a strong but potentially modifiable risk factor for OA incidence, progression, and disability.97 There is growing recognition that pain may lead patients with OA who are obese to alter how they perform physical activities so as to decrease load on joints and that efforts to avoid pain may set in motion vicious cycles that contribute to disability and pain.134 Individuals with OA are known to be less active than their age-matched peers, and efforts to avoid pain by decreasing activity may lead to a sedentary lifestyle that makes it difficult to lose weight.42

Although these effects could be related to altered gait and increased joint stresses secondary to increased body weight,96 there is also evidence that obesity leads to systemic inflammation29,154 that may interact with biomechanical factors to promote the progressive degradation of joint cartilage in joints of the hand.41 The benefits of exercise in an arthritic population include not only weight loss, but also decreased systemic inflammation, increased muscle strength, flexibility, energy, a sense of well-being, higher levels of self-efficacy, use of more active and adaptive coping strategies, enhanced quality of sleep, decreased blood pressure, and fewer heart attacks.104

Clinical and animal studies of joint loading have provided strong evidence that abnormal loads can lead to alterations in the composition, structure, metabolism, and mechanical properties of articular cartilage and other joint tissues.64 Abnormal loading may be caused by various factors such as obesity, immobilization, joint instability, overuse, or trauma. A recent study showed that there is considerable cartilage thinning caused by decreased joint loading subsequent to spinal cord injury.153 Conversely, obesity is strongly associated with OA,108 and a decrease of 5 kg of body weight can decrease the risk of OA by more than 50%.42 Altered joint loading attributable to instability or injury of the joint is now well known to be a major risk factor for the onset and progression of OA.17,68 Joint instability, induced by ligament transection50,118 or meniscectomy65,101 also may lead to joint degeneration. These procedures result in profound changes in joint tissues that mimic changes seen in early human OA, including increased hydration, collagen disruption, and matrix turnover accompanied by decreased tissue stiffness in tension, compression, and shear.2,20,35,39,59,95,125,131,133 Articular cartilage and synovial fluid from these models of OA show notable increases in various biomarkers85 that are correlated with histologic damage in the joint.19 Similarly, the presence of these biomarkers is increased in cartilage in a coronal step-off model of articular fracture,87 suggesting that common pathways may be responsible for the metabolic changes in these two models.

Back to Top | Article Outline

Cartilage Inflammation in OA

Although the role of inflammation in OA has been long debated,121 considerable evidence now confirms the role of proinflammatory cytokines and mediators in this disease,94 and their potential in various therapies (Table 1).46 For example, the catabolism of osteoarthritic cartilage is thought to involve the action of proinflammatory cytokines such as interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-α).51,94,156 Interleukin-1 down-regulates extracellular matrix (ECM) synthesis and up-regulates metalloprotease synthesis through production of nitric oxide (NO) in chondrocytes.113 Furthermore, IL-1 receptor antagonist (IL-1Ra) has been shown to be an effective therapeutic agent in animal models of arthritis and in human rheumatoid arthritis.37 After traumatic joint injury, a transient increase occurs in IL-1 and TNF-α concentrations in chondrocytes and articular cartilage.117

Table 1

Table 1

Of importance to an understanding of OA is the finding that inflammation and cartilage destruction may be separate pathogenic events; as such, therapeutic interventions for one aspect of the disease may or may not influence the other aspect. In this respect, IL-1 seems more potent in its ability to cause cartilage degradation, whereas TNF-α seems to be responsible for inflammatory events.148 The two isoforms of IL-1 (α and β) show similar potency, but IL-1α seems to be active in early synovial inflammation whereas IL-1β is the more dominant cytokine in advanced disease.150 Inhibition of nitric oxide synthase 2 (NOS2) and NO production prevents IL-1β-mediated suppression of proteoglycan and Type II collagen synthesis and increased expression of metalloproteases in chondrocytes, showing that NO acts as an endogenous mediator of the catabolic actions of IL-1β.

Other cytokines, such as IL-6 and IL-17 have been implicated in cartilage degradation and inflammation.148 Importantly, there is evidence for synergy in the interaction of these cytokines in the stimulation of cartilage breakdown127 and the production of inflammatory mediators.84 The mechanism of action of IL-1 may in fact be through the upregulation of IL-6.106 Human osteoarthritic cartilage releases sufficient IL-1 to upregulate chondrocyte production of IL-6.9 In vitro, human synoviocytes spontaneously release IL-6 in a manner that is increased by IL-1 and TNF-α.55 Interleukin 6 levels have been correlated with pain in the temporomandibular joint,137 and IL-6 synergizes with IL-1 to promote collagen degradation in cartilage.127

Back to Top | Article Outline

The Roles of NO and Prostaglandins in Cartilage

The action of these inflammatory cytokines seems to be regulated by the small proinflammatory mediators NO and prostaglandin E2 (PGE2).62,69,71 These mediators are elevated in the articular cartilage, synovium, and synovial fluid of osteoarthritic and rheumatoid joints3,24,38,53,62,69 and serve as potential therapeutic targets for OA.

Nitric oxide is a gaseous, short-acting signaling molecule with multiple important physiologic and pathologic functions.11,100,103 In the presence of oxygen, NO is converted rapidly (within seconds) to nitrite and nitrate, substances which generally are not bioactive.140 However, on reacting with O2, NO may form peroxynitrite (OONO), a toxic and reactive molecule. Nitric oxide is formed during the conversion of arginine to citrulline by the nitric oxide synthase (NOS) enzymes. There are three forms of NOS encoded by three different genes, NOS1, NOS2, and NOS3. Inducible NOS (iNOS or NOS2) was described initially in mononuclear phagocytes, and seems to be the primary NOS enzyme in chondrocytes.141 Nitric oxide synthase 2 can produce high levels of NO and most commonly is associated with inflammation in arthritic disorders.53 Inhibition of NO production using NOS2-specific inhibitors can considerably reduce disease progression in animal models of OA.24,38,114,143

The prostaglandins are important mediators of pain and inflammation in arthritis61 and are the prime target of most current therapies for OA. Prostaglandin E2 is a prostanoid synthesized by the cyclooxygenase (COX) enzymes that catalyze the conversion of arachidonic acid and oxygen to prostaglandin H2 (PGH2), the committed step in prostanoid biosynthesis. Increased prostaglandin synthesis is a cellular response to activation by proinflammatory stimuli,151 and nonsteroidal antiinflammatory drugs (NSAIDS) compete directly with arachidonic acid binding to the cyclooxygenase site and inhibit COX activity. Aspirin covalently modifies and irreversibly inhibits COX, whereas other NSAIDS such as ibuprofen and indomethacin act as reversible competitive inhibitors. Cyclooxygenase exists as three isoforms. Cyclooxygenase-1 is constitutive and exists in endothelium, stomach, kidney, and platelets, where it regulates some normal physiologic functions such as gastric mucosal cytoprotection, maintenance of renal blood flow, and function and platelet aggregation.26,155 Inducible COX (COX2) is the isoform associated with inflammatory responses and most likely is responsible for the elevated PGE2 levels in arthritis.1 Inducible–COX-specific inhibitors such as NS398 and celecoxib are time-dependent, reversible inhibitors of COX2, and display little inhibition of COX1. Cyclooxygenase-3 is a distinct isoenzyme of COX1 and has been shown to be the putative target for acetaminophen and several other analgesic or antipyretic drugs.22

Increased prostanoid synthesis and COX2 expression occur in arthritic cartilage, compared with nonarthritic cartilage.1 Prostaglandin E2 is a pleiotropic bioregulator with the ability to alter the expression of many target genes involved in the pathophysiology of arthritic diseases. Because cartilage is avascular, it is likely that effects of PGE2 are through paracrine and autocrine mechanisms. Cytokine stimulation of articular cartilage leads to PGE2 release because of increased COX2 activity.48,91 Prostaglandin E2 plays a role in the regulation of chondrocyte proliferation and synthesis of extracellular components.33 The effects of PGE2 are dose dependent and can have opposite effects on matrix biosynthesis depending on concentration.31,52 Prostaglandin E2 also can exert anticatabolic and antiinflammatory effects and can potently downregulate the expression and synthesis of inflammatory cytokines IL-1, and TNF-α, and NOS2, and metalloproteases 1 and 3.12,32,75,98

Cyclooxygenase 2 inhibitors have provided an alternative to nonspecific NSAIDs in the treatment of arthritis. They are effective therapeutic agents for OA and rheumatoid arthritis and also attenuate inflammation and hyperalgesia in several animal models of arthritis.6,151 Cyclooxygenase-2 expression is upregulated in various cell types by proinflammatory cytokines and downregulated by antiinflammatory cytokines and glucocorticoid hormones. Cyclooxygenase-2 is expressed in inflamed synovial tissue.13,25,30 Newer drugs that have high selectivity against COX2 such as celecoxib, rofecoxib, or valdecoxib have proven potent anti-inflammatory compounds with reduced side effects.36,115 However, because of the potential influence of prostaglandins on cartilage matrix turnover, the effect of COX2 inhibition on chondrocyte activity is unclear,77 particularly with respect to mechanical stress.

Furthermore, there is growing evidence that the COX enzymes, and particularly COX1, are integrally involved in bone repair,49 potentially by regulating the differentiation of mesenchymal stem cells into the osteoblast lineage.158 These recent findings support the notion that COX expression and prostanoid synthesis may play anabolic and catabolic effects on joint tissues. The role of these enzyme systems on the repair of articular fractures remains to be determined.

Importantly, there seems to be considerable interaction between the NOS and COX systems. Prostanoids can reduce NOS2 expression and NO production,92 and NO modulates PGE2 formation.130,152 Arginine analogs such as NG-monomethyl L-arginine (NMMA) may be antiinflammatory by inhibiting COX2 and NOS.129 Furthermore, aspirin (in high doses) can inhibit cyclooxygenase and NOS2.4 Modulation of NO levels or NOS expression may influence prostaglandin synthesis129,130 through the altered transcription of COX genes, modulation of COX activity, or modification of prostaglandin-metabolizing enzymes. In cartilage, NO apparently inhibits the stimulation of prostaglandin production by IL-1 or mechanical stress.21,44,45 Considerable interactions exist between mechanical stress and cytokines in the regulation of COX2 and NOS2 expression and PGE2 and NO production as they relate to inflammation (Fig 1).

Fig 1.

Fig 1.

Back to Top | Article Outline

Cartilage Injury and Inflammation

Injury to articular cartilage most often results from a single or repeated impact load. Impact loading (a rapid increase of force across the joint) can be expected to produce a highly nonuniform combination of tensile, compressive, and shear stresses and strains132 in addition to very high hydrostatic pressures through the cartilage layer.8 Impact loading can cause acute damage to the joint, but there is little evidence for progressive joint degeneration in the absence of articular fracture or repetitive loading.34,107,122,144 The effects of impact loading on chondrocyte activity in vivo have not been studied extensively, particularly with respect to the role of inflammatory mediators. However, a previous study showed the presence of synovial inflammation following repeated impact of the joint.89 Furthermore, there is evidence of the upregulation of arachidonic acid, IL-1, TNF-α, and the metalloprotease stromelysin (MMP-3) in cartilage after joint impact in the absence of articular fracture.117

Articular fractures can result in the rapid onset of posttraumatic arthritis, although the cellular basis of this response is not well defined. Displaced articular fractures result in physical disruption of articular cartilage and the underlying subchondral bone. It commonly is thought that articular impaction injury also must occur in this setting. However, little is known about the local inflammatory changes in the joint resulting after an articular fracture. In general, trauma increases local and systemic concentrations of proinflammatory cytokines such as IL-6 and IL-8.66,116 Increased circulating levels of cytokines after bodily trauma are predictive of injury severity and clinical outcome.47,63,142 Injury to the joints or skeleton can transiently increase the levels of proinflammatory cytokines locally70 and systemically.112 Such a systemic increase in inflammatory cytokines is thought to be closely related to a prolonged period of shock.112 Furthermore, short-term exposure of cartilage to blood (as would be expected after a displaced articular fracture) can induce chondrocyte apoptosis.67 However, it is not known whether a systemic increase in inflammatory cytokines has an effect on the outcome of an articular fracture.

It also is clear that a displaced fracture alters the loading environment of the joint.5,10,16,76,109,110 in a manner that can lead to posttraumatic arthritis.82,83 Data regarding physical or inflammatory changes are not known, and an understanding of the role of inflammation in the development of posttraumatic arthritis is still evolving. Nonetheless, inflammatory mediators and cytokines seem to play an important role in other models of OA based on altered joint loading, which may provide additional insight on the relationship between biomechanical factors and inflammation.

Additional information on the potential interaction of mechanical stress and joint inflammation comes from studies of rheumatoid arthritis. Physical activity for patients with rheumatoid arthritis has been controversial, especially for patients with active disease. With increasing numbers of controlled, blinded trials, evidence has emerged of the benefits of exercise on joint pain in the uninflamed joint. Exercise alters immune function in a way that seems helpful in regulating inflammation. Furthermore, there is evidence that patients can tolerate a program of regular moderate aerobic exercise, and such exercise substantially enhances physical performance without exacerbating either clinical or immunologic markers of the disease process.104,136 In other studies, training of the muscles acting over the swollen joints resulted in a considerable decrease in the number of swollen joints.90 In fact, high-intensity strength training now is thought to be feasible and safe in selected patients and leads to considerable improvements in strength, pain, and fatigue without exacerbating disease activity or joint pain.124

In an acutely inflamed joint, there still is controversy as to the benefits or detriment of mechanical stress (rest versus exercise). Historically, rest therapy and immobilization have been prescribed for the inflamed joint, often to prevent fatigue.138 Of particular interest is the finding that running exercise considerably increases cartilage destruction in the joints of hamsters that have been injected with lipopolysaccharide (LPS) to induce inflammation. This finding suggests that mechanical stress applied to cartilage in the presence of inflammation enhances the breakdown of the collagen matrix, and may increase further the inflammatory response by the release of cartilage breakdown products into the synovial fluid.135

These in vivo studies emphasize the relationship between mechanical loading and the health of the joint and suggest that the normal regulation of chondrocyte activity by mechanical factors may be influenced adversely by the presence of proinflammatory mediators and cytokines in the joint. Considered together, these studies suggest that a critical amount of joint loading and a specific pattern of joint loading are required for the normal homeostatic balance of cartilage anabolism and catabolism. The interactions of biomechanical and inflammatory mechanisms involved in the progression of cartilage degeneration are not known. Currently, there is considerable evidence to implicate the role of various cytokines, specifically IL-1, IL-6, and TNF-α, in these processes.149 One interpretation of the disuse and exercise studies is that the frequency of loading of articular cartilage influences the rate of matrix synthesis and breakdown. Conversely, studies of progressive joint degeneration present evidence that degenerative changes are initiated by hyperphysiologic magnitudes of loading or by alterations in the normal loading pattern of the joint because of joint instability or articular fracture. Considered together, these findings support the notion that altered patterns and magnitudes of stress in the joint after a displaced intraarticular fracture may play a role in posttraumatic arthritis.

Back to Top | Article Outline

Biomechanical Factors and Inflammation in Cartilage: In Vitro Studies

In vitro explant models of mechanical loading provide systems in which the biomechanical and biochemical environments of the chondrocytes can be better controlled, compared with the in vivo situation. Considerable research effort has been directed toward understanding the processes by which biophysical signals are converted to a biochemical signal by the chondrocyte population. Clarification of the specific biophysical factors and biologic signaling mechanisms in normal and inflamed cartilage would provide a better understanding of cartilage physiology and repair and also may yield new insights on the pathogenesis of posttraumatic OA. This information potentially could reveal new targets for disease prevention or treatment.

Explant models of cartilage loading have been used in numerous different loading configurations, including unconfined compression, indentation, tension, and osmotic and hydrostatic pressure.14,18,54,56–58,74,111,123,128,145 The general consensus of these studies is that static compression suppresses matrix biosynthesis, and cyclic and intermittent loading stimulate chondrocyte metabolism. These responses have been reported over a wide range of loading magnitudes, and exhibit a stress-dose dependency.60

Numerous in vitro studies have investigated supraphysiologic loading of cartilage using one impact load or repeated impact loads.27,40,72,73,88,119,146 These studies have shown acute changes in the biomechanical properties, metabolic activity, and cell viability of articular cartilage that are similar to those occurring with in vivo impact. These in vitro studies suggest that the rate and the magnitude of loading can have considerable effects on cartilage health and apoptosis, and that the effects on cell death and matrix loss after injury can vary considerably with depth in the cartilage layer.23,34,72,73,86,120

Mechanical stress also can influence NO production by chondrocytes,28,81 and increased IL-6, NO, PGE2, and proteoglycan synthesis occurs in isolated chondrocytes in response to fluid shear stress.99,139 Chondrocytes embedded in their own ECM show similar increases in the production of proinflammatory mediators with stress,43–45 although chondrocytes embedded in an agarose matrix show an opposite effect81 suggesting that interactions with the native ECM can influence this response. Other studies have shown that static and intermittent mechanical compression influences the synthesis of NO44 and PGE2 with considerable interaction between the NOS2 and COX2 pathways.21 In an in vitro model, intermittent compression of cartilage explants in the presence of the specific NOS2 inhibitor 1400W caused an additional increase in PGE2 production (40-fold increase compared with control), indicating that inducible NO has a negative feedback role in the prostanoid pathway in articular cartilage. Because the effects of mechanical loading are not additive with those of exogenous PGE2, investigators have hypothesized that prostanoids play a role in the degenerative and repair process in arthritis, where elevated intraarticular levels of PGE2 are present.147 These findings may have important implications regarding the pathogenesis of arthritis and the development of new physical and pharmacologic interventions for arthritis treatment.

Back to Top | Article Outline

DISCUSSION

There now is considerable evidence that proinflammatory mediators and cytokines contribute to cartilage injury and repair, particularly in the context of OA. There is also evidence that these mediators are involved in the events after cartilage injury and articular fracture that lead to posttraumatic arthritis. Changes in the mechanical environment, an important regulator of cartilage physiology, seem to play an important role in modulating the production of proinflammatory mediators in articular cartilage, whereas injury of the joint may lead to considerable increases in local concentrations of proinflammatory cytokines. Numerous different but interacting cytokines have been implicated in the inflammatory response of articular cartilage (Table 1), and several recent approaches for OA therapy have targeted these molecules.46 In vivo findings indicate that altered joint loading can cause deleterious cartilage changes similar to those of early OA, and these effects can be ameliorated by inhibition of inflammatory cascades. A more detailed understanding of the inflammatory changes occurring in joint tissues in response to traumatic injury may provide new insights into the mechanisms of disease progression in posttraumatic arthritis. Nonetheless, inflammation is an important aspect of tissue repair, and recent reports suggest that the COX enzymes are integrally involved in bone healing. Therefore, any therapeutic manipulation of inflammatory pathways after articular fracture should be approached with caution.

The biomechanical and biologic mechanisms involved in the transduction of mechanical loads to an intracellular response remain to be elucidated. In situ explant studies confirm that mechanical load may be a potent regulator of matrix metabolism and cell viability. Furthermore, mechanical stress can influence the production of the proinflammatory mediators NO and PGE2 through the activation of NOS2 and COX2, respectively, with considerable evidence of cross-talk between these pathways. These findings further support the potential of these pathways as therapeutic targets, but also suggest that agents such as COX2 inhibitors or NOS2 inhibitors that are designed to combat one inflammatory pathway may affect other pathways, particularly under physiologic loading conditions. Together, these findings suggest that additional knowledge of the interaction of inflammatory and biomechanical factors in regulating cartilage metabolism would be beneficial to understanding the onset and progression of posttraumatic arthritis.

Back to Top | Article Outline

References

1. Abramson SB: The role of COX-2 produced by cartilage in arthritis. Osteoarthritis Cartilage 7:380–381, 1999.
2. Altman RD, Tenenbaum J, Latta L, et al: Biomechanical and biochemical properties of dog cartilage in experimentally induced osteoarthritis. Ann Rheum Dis 43:83–90, 1984.
3. Amin AR, Di Cesare PE, Vyas P, et al: The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: Evidence for up-regulated neuronal nitric oxide synthase. J Exp Med 182:2097–2102, 1995.
4. Amin AR, Vyas P, Attur M, et al: The mode of action of aspirin-like drugs: Effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 92:7926–7930, 1995.
5. Anderson DD, Bell AL, Gaffney MB, Imbriglia JE: Contact stress distributions in malreduced intraarticular distal radius fractures. J Orthop Trauma 10:331–337, 1996.
6. Anderson GD, Hauser SD, McGarity KL, et al: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis. J Clin Invest 97:2672–2679, 1996.
7. Anonymous: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43:1905–1915, 2000.
8. Ateshian GA, Lai WM, Zhu WB, Mow VC: An asymptotic solution for the contact of two biphasic cartilage layers. J Biomech 27:1347–1360, 1994.
9. Attur MG, Patel IR, Patel RN, Abramson SB, Amin AR: Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians 110:65–72, 1998.
10. Baratz ME, Des Jardins J, Anderson DD, Imbriglia JE: Displaced intra-articular fractures of the distal radius: The effect of fracture displacement on contact stresses in a cadaver model. J Hand Surg 21A:185–188, 1996.
11. Beckman JS, Crow JP: Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 21:330–334, 1993.
12. Blanco FJ, Lotz M: IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp Cell Res 218:319–325, 1995.
13. Bombardieri S, Cattani P, Giabattoni G, et al: The synovial prostaglandin system in chronic inflammatory arthritis: Differential effects of steroidal and non-steroidal antiinflammatory drugs. Br J Pharmacol 73:893–901, 1981.
14. Bonassar LJ, Grodzinsky AJ, Srinivasan A, Davila SG, Trippel SB: Mechanical and physicochemical regulation of the action of insulin-like growth factor-I on articular cartilage. Arch Biochem Biophys 379:57–63, 2000.
15. Brandt KD, Doherty M, Lohmander LS: Osteoarthritis. New York, Oxford University Press, 1998.
16. Brown TD, Anderson DD, Nepola JV, et al: Contact stress aberrations following imprecise reduction of simple tibial plateau fractures. J Orthop Res 6:851–862, 1988.
17. Buckwalter JA: Osteoarthritis and articular cartilage use, disuse, and abuse: Experimental studies. J Rheumatol 43:13–15, 1995.
18. Burton-Wurster N, Vernier-Singer M, Farquhar T, Lust G: Effect of compressive loading and unloading on the synthesis of total protein, proteoglycan, and fibronectin by canine cartilage explants. J Orthop Res 11:717–729, 1993.
19. Carlson CS, Guilak F, Vail TP, Gardin JF, Kraus VB: Synovial fluid biomarker levels predict articular cartilage damage following complete medial meniscectomy in the canine knee. J Orthop Res 20:92–100, 2002.
20. Carney SL, Billingham ME, Muir H, Sandy JD: Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental osteoarthritis. J Orthop Res 2:201–206, 1984.
21. Cernanec J, Guilak F, Weinberg JB, Pisetsky DS, Fermor B: Influence of hypoxia and reoxygenation on cytokine-induced production of proinflammatory mediators in articular cartilage. Arthritis Rheum 46:968–975, 2002.
22. Chandrasekharan NV, Dai H, Roos KL, et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci U S A 99:13926–13931, 2002.
23. Chen C-T, Burton-Wurster N, Borden C, et al: Chondrocyte necrosis and apoptosis in impact damaged articular cartilage. J Orthop Res 19:703–711, 2001.
24. Clancy RM, Amin AR, Abramson SB: The role of nitric oxide in inflammation and immunity. Arthritis Rheum 41:1141–1151, 1998.
25. Crofford LJ, Wilder RL, Ristimaki AP, et al: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: Effects of interleukin-1beta, phorbol ester, and corticosteroids. J Clin Inv 93:1095–1101, 1994.
26. Cryer B, Dubois A: The advent of highly selective inhibitors of cyclooxygenase: A review. Prostaglandins Other Lipid Mediat 56:341–361, 1998.
27. D’Lima DD, Hashimoto S, Chen PC, Colwell Jr CW, Lotz MK: Human chondrocyte apoptosis in response to mechanical injury. Osteoarthritis Cartilage 9:712–719, 2001.
28. Das P, Schurman DJ, Smith RL: Nitric oxide and G proteins mediate the response of bovine articular chondrocytes to fluid-induced shear. J Orthop Res 15:87–93, 1997.
29. Das UN: Is obesity an inflammatory condition? Nutrition 17:953–966, 2001.
30. Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW: The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol 2:335–357, 1984.
31. Di Battista JA, Dore S, Martel-Pelletier J, Pelletier JP: Prostaglandin E2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: Identification of an effector autocrine loop involving insulin-like growth factor I. Mol Cell Endocrinol 123:27–35, 1996.
32. Di Battista JA, Martel-Pelletier J, Fujimoto N, et al: Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts: Mediation by cyclic-AMP signalling pathway. Lab Invest 71:270–278, 1994.
33. Dingle J: Cartilage maintenance in osteoarthritis: Interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair. J Rheumatol Suppl 28:30–37, 1991.
34. Donohue JM, Buss D, Oegema Jr TR, Thompson Jr RC: The effects of indirect blunt trauma on adult canine articular cartilage. J Bone Joint Surg 65A:948–957, 1983.
35. Elliott DM, Guilak F, Vail TP, Wang JY, Setton LA: Tensile properties of articular cartilage are altered by meniscectomy in a canine model of osteoarthritis. J Orthop Res 17:503–508, 1999.
36. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44:423–433, 1995.
37. Evans CH, Ghivizzani SC, Robbins PD: Blocking cytokines with genes. J Leukoc Biol 64:55–61, 1998.
38. Evans CH, Stefanovic-Racic M, Lancaster Jr JR: Nitric oxide and its role in orthopaedic disease. Clin Orthop 312:275–294, 1995.
39. Eyre DR, McDevitt CA, Billingham ME, Muir H: Biosynthesis of collagen and other matrix proteins by articular cartilage in experimental osteoarthrosis. Biochem J 188:823–837, 1980.
40. Farquhar T, Xia Y, Mann K, et al: Swelling and fibronectin accumulation in articular cartilage explants after cyclical impact. J Orthop Res 14:417–423, 1996.
41. Felson DT, Chaisson CE: Understanding the relationship between body weight and osteoarthritis. Baill Clin Rheum 11:671–681, 1997.
42. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ: Weight loss reduces the risk for symptomatic knee osteoarthritis in women: The Framingham Study. Ann Intern Med 116:535–539, 1992.
43. Fermor B, Haribabu B, Brice Weinberg J, Pisetsky DS, Guilak F: Mechanical stress and nitric oxide influence leukotriene production in cartilage. Biochem Biophys Res Commun 285:806–810, 2001.
44. Fermor B, Weinberg JB, Pisetsky DS, et al: The effects of static and intermittent compression on nitric oxide production in articular cartilage explants. J Orthop Res 19:729–737, 2001.
45. Fermor B, Weinberg JB, Pisetsky DS, et al: Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. Osteoarthritis Cartilage 10:792–798, 2002.
46. Fernandes JC, Martel-Pelletier J, Pelletier JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology 39:237–246, 2002.
47. Gebhard F, Pfetsch H, Steinbach G, et al: Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg 135:291–295, 2000.
48. Geng Y, Blanco FJ, Cornelisson M, Lotz M: Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 155:796–801, 1995.
49. Gerstenfeld LC, Thiede M, Seibert K, et al: Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 21:670–675, 2003.
50. Gilbertson EMM: Development of periarticular osteophytes in experimentally induced osteoarthrosis in the dog. Ann Rheum Dis 34:12–25, 1975.
51. Goldring MB, Suen LF, Yamin R, Lai WF: Regulation of collagen gene expression by prostaglandins and interleukin-1beta in cultured chondrocytes and fibroblasts. Am J Ther 3:9–16, 1996.
52. Goldring MB: Osteoarthritis and cartilage: The role of cytokines. Curr Rheumatol Rep 2:459–465, 2000.
53. Grabowski PS, Wright PK, Vanthof RJ, et al: Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 36:651–655, 1997.
54. Gray ML, Pizzanelli AM, Grodzinsky AJ, Lee RC: Mechanical and physiochemical determinants of the chondrocyte biosynthetic response. J Orthop Res 6:777–792, 1988.
55. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M: Synovium as a source of interleukin 6 in vitro: Contribution to local and systemic manifestations of arthritis. J Clin Invest 83:585–592, 1989.
56. Guilak F: Compression-induced changes in the shape and volume of the chondrocyte nucleus. J Biomech 28:1529–1542, 1995.
57. Guilak F, Meyer BC, Ratcliffe A, Mow VC: The effects of matrix compression on proteoglycan metabolism in articular cartilage explants. Osteoarthritis Cartilage 2:91–101, 1994.
58. Guilak F, Mow VC: The mechanical environment of the chondrocyte: A biphasic finite element model of cell-matrix interactions in articular cartilage. J Biomech 33:1663–1673, 2000.
59. Guilak F, Ratcliffe A, Lane N, Rosenwasser MP, Mow VC: Mechanical and biochemical changes in the superficial zone of articular cartilage in canine experimental osteoarthritis. J Orthop Res 12:474–484, 1994.
60. Guilak F, Sah RL, Setton LA: Physical Regulation of Cartilage Metabolism. In Eds V. C. Mow, and W. C. Hayes (eds) Basic Orthopaedic Biomechanics. Philadelphia, Lippincott-Raven 179–207, 1997.
61. Harris ED: Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 322:1277–1289, 1990.
62. Hashimoto S, Takahashi K, Ochs RL, et al: Nitric oxide production and apoptosis in cells of the meniscus during experimental osteoarthritis. Arthritis Rheum 42:2123–2131, 1999.
63. Hecke F, Schmidt U, Kola A, et al: Circulating complement proteins in multiple trauma patients: Correlation with injury severity, development of sepsis, and outcome. Crit Care Med 25:2015–2024, 1997.
64. Helminen HJ, Jurvelin J, Kiviranta I, et al: Joint Loading Effects on Articular Cartilage: A Historical Review. In Helminen HJ, Kiviranta I, Tammi M, et al (eds). Joint Loading: Biology and Health of Articular Structures. Bristol, Wright and Sons 1–46, 1987.
65. Hoch DH, Grodzinsky AJ, Koob TJ, Albert ML, Eyre DR: Early changes in material properties of rabbit articular cartilage after meniscectomy. J Orthop Res 1:4–12, 1983.
66. Holzheimer RG, Steinmetz W: Local and systemic concentrations of pro- and anti-inflammatory cytokines in human wounds. Eur J Med Res 5:347–355, 2000.
67. Hooiveld M, Roosendaal G, Wenting M, et al: Short-term exposure of cartilage to blood results in chondrocyte apoptosis. Am J Pathol 162:943–951, 2003.
68. Howell DS, Treadwell BV, Trippel SB: Etiopathogenesis of Osteoarthritis. In Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ, (eds). Osteoarthritis: Diagnosis and Medical/Surgical Management. Philadelphia, W.B. Saunders 233–252, 1992.
69. Hughes FJ, Buttery LD, Hukkanen MV, et al: Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts in vitro. J Biol Chem 274:1776–1782, 1999.
70. Irie K, Uchiyama E, Iwaso H: Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 10:93–96, 2003.
71. Jang D, Murrell GAC: Nitric oxide in arthritis. Free Radic Biol Med 24:1511–1519, 1998.
72. Jeffrey JE, Gregory DW, Aspden RM: Matrix damage and chondrocyte viability following a single impact load on articular cartilage. Arch Biochem Biophys 322:87–96, 1995.
73. Jeffrey JE, Thomson LA, Aspden RM: Matrix loss and synthesis following a single impact load on articular cartilage in vitro. Biochim Biophys Acta 1334:223–232, 1997.
74. Kim YJ, Sah RL, Grodzinsky AJ, Plaas AH, Sandy JD: Mechanical regulation of cartilage biosynthetic behavior: Physical stimuli. Arch Biochem Biophys 311:1–12, 1994.
75. Knudsen PJ, Dinarello CA, Strom TB: Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137:3189–3194, 1986.
76. Konrath GA, Hamel AJ, Guerin J, et al: Biomechanical evaluation of impaction fractures of the femoral head. J Orthop Trauma 13:407–413, 1999.
77. Kraus V: COX-2 Inhibitors and non-steroidal anti-inflammatory drugs in the management of arthritis. Foot Ankle Clin 8:187–200, 2003.
78. Kraus VB: Pathogenesis and treatment of osteoarthritis. Med Clin North Am 81:85–112, 1997.
79. Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC: Articular cartilage and osteoarthritis. Raven Press, New York, 1992.
80. Lane NE: Physical activity at leisure and risk of osteoarthritis. Ann Rheum Dis 55:682–684, 1996.
81. Lee DA, Frean SP, Lees P, Bader DL: Dynamic mechanical compression influences nitric oxide production by articular chondrocytes seeded in agarose. Biochem Biophys Res Commun 251:580–585, 1998.
82. Lefkoe TP, Trafton PG, Ehrlich MG, et al: An experimental model of femoral condylar defect leading to osteoarthrosis. J Orthop Trauma 7:458–467, 1993.
83. Lefkoe TP, Walsh WR, Anastasatos J, Ehrlich MG, Barrach HJ: Remodeling of articular step-offs: Is osteoarthrosis dependent on defect size? Clin Orthop 314:253–265, 1995.
84. LeGrand A, Fermor B, Fink C, et al: Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E-2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 44:2078–2083, 2001.
85. Lindhorst E, Vail TP, Guilak F, et al: Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. J Orthop Res 18:269–280, 2000.
86. Loening AM, James IE, Levenston ME, et al: Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis. Arch Biochem Biophys 381:205–212, 2000.
87. Lovasz G, Park SH, Ebramzadeh E, et al: Characteristics of degeneration in an unstable knee with a coronal surface step-off. J Bone Joint Surg 83B:428–436, 2001.
88. Lucchinetti E, Adams CS, Horton Jr WE, Torzilli PA: Cartilage viability after repetitive loading: A preliminary report. Osteoarthritis Cartilage 10:71–81, 2002.
89. Lukoschek M, Boyd RD, Schaffler MB, Burr DB, Radin EL: Comparison of joint degeneration models. Surgical instability and repetitive impulsive loading. Acta Orthop Scand 57:349–353, 1986.
90. Lyngberg K, Danneskiold-Samsoe B, Halskov O: The effect of physical training on patients with rheumatoid arthritis: changes in disease activity, muscle strength and aerobic capacity: A clinically controlled minimized cross-over study. Clin Exp Rheum 6:253–260, 1988.
91. Lyons-Giordano B, Pratta M, Galbraith W, Davis G, Arner E: Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. Exp Cell Res 206:58–62, 1993.
92. Marotta P, Sautebin L, Di Rosa M: Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774. Br J Pharmacol 107:640–641, 1992.
93. Marsh JL, Buckwalter J, Gelberman R, et al: Articular fractures: Does an anatomic reduction really change the result? J Bone Joint Surg 84A:1259–1271, 2002.
94. Martel-Pelletier J, Alaaeddine N, Pelletier JP: Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 4:D694–D703, 1999.
95. McDevitt CA, Muir H: Biochemical changes in the cartilage of the knee in experimental and natural osteoarthritis in the dog. J Bone Joint Surg 58B:94–101, 1976.
96. Messier SP: Osteoarthritis of the knee and associated factors of age and obesity: Effects on gait. Med Sci Sports Exerc 26:1446–1452, 1994.
97. Messier SP, Loeser RF, Mitchell MN, et al: Exercise and weight loss in obese older adults with knee osteoarthritis: A preliminary study. J Am Geriatr Soc 48:1062–1072, 2000.
98. Milano S, Arcoleo F, Dieli M, et al: Prostaglandin E2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774. Prostaglandins 49:105–115, 1995.
99. Mohtai M, Gupta MK, Donlon B, et al: Expression of interleukin-6 in osteoarthritic chondrocytes and effects of fluid-induced shear on this expression in normal human chondrocytes in vitro. J Orthop Res 14:67–73, 1996.
100. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002–2012, 1993.
101. Moskowitz RW, Davis W, Sammarco J: Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. Arthritis Rheum 16:397–405, 1973.
102. Mow VC, Ratcliffe A, Poole AR: Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures. Biomaterials 13:67–97, 1992.
103. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051–3064, 1992.
104. Neuberger GB: Press AN, Lindsley HB, et al: Effects of exercise on fatigue, aerobic fitness, and disease activity measures in persons with rheumatoid arthritis. Res Nurs Health 20:195–204, 1997.
105. Newberry WN, Mackenzie CD, Haut RC: Blunt impact causes changes in bone and cartilage in a regularly exercised animal model. J Orthop Res 16:348–354, 1998.
106. Nietfeld JJ, Wilbrink B, Helle M, et al: Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 33:1695–1701, 1990.
107. Oegema Jr TR, Lewis JL, Thompson Jr RC: Role of acute trauma in development of osteoarthritis. Agents Actions 40:220–223, 1993.
108. Oliveria SA, Felson DT, Cirillo PA, Reed JI, Walker AM: Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 10:161–166, 1999.
109. Olson SA, Bay BK, Chapman MW, Sharkey NA: Biomechanical consequences of fracture and repair of the posterior wall of the acetabulum. J Bone Joint Surg 77A:1184–1192, 1995.
110. Olson SA, Bay BK, Pollak AN, Sharkey NA, Lee T: The effect of variable size posterior wall acetabular fractures on contact characteristics of the hip joint. J Orthop Trauma 10:395–402, 1996.
111. Palmoski MJ, Brandt KD: Effects of static and cyclic compressive loading on articular cartilage plugs in vitro. Arthritis Rheum 27:675–681, 1984.
112. Pape HC, van Griensven M, Rice J, et al: Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: Determination of the clinical relevance of biochemical markers. J Trauma 50:989–1000, 2001.
113. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J: Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 19:545–568, 1993.
114. Pelletier JP, Jovanovic D, Fernandes JC, et al: Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 41:1275–1286, 1998.
115. Penning TD, Talley JJ, Bertenshaw SR, et al: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347–1365, 1997.
116. Perl M, Gebhard F, Knoferl MW, et al: The pattern of preformed cytokines in tissues frequently affected by blunt trauma. Shock 19:299–304, 2003.
117. Pickvance EA, Oegema Jr TR, Thompson Jr RC: Immunolocalization of selected cytokines and proteases in canine articular cartilage after transarticular loading. J Orthop Res 11:313–323, 1993.
118. Pond MJ, Nuki G: Experimentally induced osteoarthritis in the dog. Ann Rheum Dis 32:387–388, 1973.
119. Quinn TM, Allen RG, Schalet BJ, Perumbuli P, Hunziker EB: Matrix and cell injury due to sub-impact loading of adult bovine articular cartilage explants: Effects of strain rate and peak stress. J Orthop Res 19:242–249, 2001.
120. Quinn TM, Grodzinsky AJ, Hunziker EB, Sandy JD: Effects of injurious compression on matrix turnover around individual cells in calf articular cartilage explants. J Orthop Res 16:490–499, 1998.
121. Radin EL: Protest the continuing common usage of the term osteoarthritis. Clin Orthop 263:310–312, 1990.
122. Radin EL, Martin RB, Burr DB, et al: Effects of mechanical loading on the tissues of the rabbit knee. J Orthop Res 2:221–234, 1984.
123. Ragan PM, Badger AM, Cook M, et al: Down-regulation of chondrocyte aggrecan and type-II collagen gene expression correlates with increases in static compression magnitude and duration. J Orthop Res 17:836–842, 1999.
124. Rall LC, Meydani SN, Kehayias JJ, Dawson-Hughes B, Roubenoff R: The effect of progressive resistance training in rheumatoid arthritis: Increased strength without changes in energy balance or body composition. Arthritis Rheum 39:415–426, 1996.
125. Ratcliffe A, Billingham ME, Saed-Nejad F, Muir H, Hardingham TE: Increased release of matrix components from articular cartilage in experimental canine osteoarthritis. J Orthop Res 10:350–358, 1992.
126. Roos H, Lauren M, Adalberth T, et al: Knee osteoarthritis after meniscectomy: Prevalence of radiographic changes after twenty-one years, compared with matched controls. Arthritis Rheum 41:687–693, 1998.
127. Rowan AD, Koshy PJ, Shingleton WD, et al: Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 44:1620–1632, 2001.
128. Sah RL, Kim YJ, Doong JY, et al: Biosynthetic response of cartilage explants to dynamic compression. J Orthop Res 7:619–636, 1989.
129. Salvemini D, Manning PT, Zweifel BS, et al: Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties of nitric oxide synthase inhibitors. J Clin Invest 96:301–308, 1995.
130. Salvemini D, Misko TP, Masferrer JL, et al: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 90:7240–7244, 1993.
131. Sandy JD, Adams ME, Billingham ME, Plaas A, Muir H: In vivo and in vitro stimulation of chondrocyte biosynthetic activity in early experimental osteoarthritis. Arthritis Rheum 27:388–397, 1984.
132. Schwartz MH, Leo PH, Lewis JL: A microstructural model for the elastic response of articular cartilage. J Biomech 27:865–873, 1994.
133. Setton LA, Mow VC, Muller FJ, Pita JC, Howell DS: Mechanical properties of canine articular cartilage are significantly altered following transection of the anterior cruciate ligament. J Orthop Res 12:451–463, 1994.
134. Sharma L: Local factors in osteoarthritis. Curr Opin Rheumatol 13:441–446, 2001.
135. Shay AK, Bliven ML, Scampoli DN, Otterness IG, Milici AJ: Effects of exercise on synovium and cartilage from normal and inflamed knees. Rheumatol Int 14:183–189, 1995.
136. Shephard RJ, Shek PN: Autoimmune disorders, physical activity, and training, with particular reference to rheumatoid arthritis. Exercise Immunol Rev 3:53–67, 1997.
137. Shinoda C, Takaku S: Interleukin-1 beta, interleukin-6, and tissue inhibitor of metalloproteinase-1 in the synovial fluid of the temporomandibular joint with respect to cartilage destruction. Oral Dis 6:383–390, 2000.
138. Smith RD, Polley HF: Rest therapy for rheumatoid arthritis. Mayo Clin Proc 53:141–145, 1978.
139. Smith RL, Donlon BS, Gupta MK, et al: Effects of fluid-induced shear on articular chondrocyte morphology and metabolism in vitro. J Orthop Res 13:824–831, 1995.
140. Stamler JS, Singel DJ, Loscalzo J: Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898–1902, 1992.
141. Stefanovic-Racic M, Stadler J, Georgescu HI, Evans CH: Nitric oxide synthesis and its regulation by rabbit synoviocytes. J Rheumatol 21:1892–1898, 1994.
142. Strecker W, Gebhard F, Rager J, et al: Early biochemical characterization of soft-tissue trauma and fracture trauma. J Trauma 47:358–364, 1999.
143. Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH: Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 7:377–379, 1999.
144. Thompson Jr RC, Oegema Jr TR, Lewis JL, Wallace L: Osteoarthrotic changes after acute transarticular load: An animal model. J Bone Joint Surg 73A:990–1001, 1991.
145. Torzilli PA, Grigiene R: Continuous cyclic load reduces proteoglycan release from articular cartilage. Osteoarthritis Cartilage 6:260–268, 1998.
146. Torzilli PA, Grigiene R, Borrelli Jr J, Helfet DL: Effect of impact load on articular cartilage: Cell metabolism and viability, and matrix water content. J Biomech Eng 121:433–441, 1999.
147. Torzilli PA, Tehrany AM, Grigiene R, Young E: Effects of misoprostol and prostaglandin E2 on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants. Prostaglandins 52:157–173, 1996.
148. Van De Loo A, Van Den Berg W: Effects of murine recombinant IL1 on synovial joints in mice: Measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 49:238–245, 1990.
149. van den Berg WB: Lessons for joint destruction from animal models. Curr Opin Rheumatol 9:221–228, 1997.
150. van den Berg WB, Joosten LA, van de Loo FA: TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheum 17:S105–S114, 1999.
151. Vane JR, Botting RM: Mechanism of action of antiinflammatory drugs. Int J Tissue React 20:3–15, 1998.
152. Vane JR, Mitchell JA, Appleton I, et al: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A 91:2046–2050, 1994.
153. Vanwanseele B, Eckstein F, Knecht H, Spaepen A, Stussi E: Longitudinal analysis of cartilage atrophy in the knees of patients with spinal cord injury. Arthritis Rheum 48:3377–3381, 2003.
154. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135, 1999.
155. Warner TD, Giuliano F, Vojnovic I, et al: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci U S A 96:7563–7568, 1999.
156. Westacott CI, Sharif M: Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 25:254–272, 1996.
157. Ytterberg SR, Mahowald ML, Krug HE: Exercise for arthritis. Baill Clin Rheum 8:161–189, 1994.
158. Zhang X, Schwarz EM, Young DA, et al: Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405–1415, 2002.
© 2004 Lippincott Williams & Wilkins, Inc.